Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 10:28:100582.
doi: 10.1016/j.eclinm.2020.100582. eCollection 2020 Nov.

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa

Affiliations

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa

Cédric B Chesnais et al. EClinicalMedicine. .

Abstract

Background: Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high Loa loa microfilarial densities (MFD). We developed the first statistical models enabling prediction of SAE risk in individuals with a given MFD.

Methods: We used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemic areas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0·36%) developed an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariate logistic models including subjects' sex, age, pre-treatment L loa and Mansonella perstans MFDs, and study region.

Findings: The models predicted that regardless of sex, about 1% of people with 20 000 L loa microfilariae per millilitre of blood (mf/mL), 10% of people with 50 000 mf/mL and about one third of those with 100 000 mf/mL will develop an SAE. For a given MFD, males have a three-fold higher risk of developing an SAE than females.

Interpretation: By enabling the prediction of post-ivermectin SAE risk in communities with known distribution of L loa MFDs, our results can guide decisions on the choice of ivermectin-based treatment strategies. They also predict that 37 SAEs were prevented in 2015 by using a Test-and-Treat strategy in the Okola District of Cameroon.

Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Développement; Mectizan Donation Program; Bill & Melinda Gates Foundation.

Keywords: Africa; Loiasis; Serious adverse events.

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

Fig. 1
Fig. 1
Predicted probabilities of developing a post-ivermectin severe adverse event according to the individual L loa microfilarial density, overall.
Fig. 2
Fig. 2
Predicted probabilities of developing a post-ivermectin of severe adverse event according to the individual L loa microfilarial density, according to the sex.

Similar articles

Cited by

References

    1. Gardon J., Gardon-Wendel N., Demanga-Ngangue Kamgno J, Chippaux J.P., Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18–22. - PubMed
    1. Kamgno J., Pion S.D., Chesnais C.B. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med. 2017;377:2044–2052. - PMC - PubMed
    1. Boussinesq M., Fobi G., Kuesel A.C. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10:i40–i48. - PMC - PubMed
    1. Lenk E.J., Moungui H.C., Boussinesq M. A test-and-not-treat strategy for onchocerciasis elimination in Loa loa co-endemic areas: cost analysis of a pilot in the Soa health district, Cameroon. Clin Infect Dis. 2019;70:1628–1635. - PMC - PubMed
    1. World Health Organization. Report of the second Meeting of the WHO Onchocerciasis Technical Advisory Subgroup, WHO, Geneva, Switzerland, 12-14 February 2018. WHO/CDS/NTD/PCT/2018.11. 2018 https://apps.who.int/iris/bitstream/handle/10665/277238/WHO-CDS-NTD-PCT-....

LinkOut - more resources